Clinical Pipeline Advanced Significantly Balance Sheet Strengthened since period end Out-licensing deal completed on pre-clinical compound (for sedation/anaesthesia) Cambridge, UK, 13 September 2007 - CeNeS, the developing CNS focused specialty pharmaceutical company, today announces its interim results for the six months to 30 June 2007. Clinical Pipeline Highlights M6G - morphine-6-glucuronide * Positive data from Phase III trial in post-operative pain announced in February 2007 * Investigational New Drug Application ("IND") approved in April 2007 * Phase I studies to support IND proceeding to plan * US phase III clinical trials preparation proceeding to plan * Active discussions ongoing with respect to potential M6G partnering deals * US, European and Japanese trademark approvals have been granted covering two families of trademarks (undisclosed) CNS 5161 * Cancer pain Phase II study commenced patient recruitment in September 2007 * Commenced development of transdermal patch formulation CNS 7056 - short acting sedation/anaesthesia * Out-licence agreement with Ono Pharmaceutical Co., Ltd ("Ono") for Japanese rights to CNS 7056 completed in August 2007 * Ono and CeNeS will develop the compound for the additional indication of anaesthesia * Key manufacturing issues resolved and final pre-clinical studies underway * Filing of IND in the US and proof of concept Phase I study planned for H1 2008 Financial Highlights * Loss after tax of £4.0 million (H1 2006: £3.6 million) * Balance sheet strengthened since period end:- - Placing to raise £5.7 million, net of expenses, in August 2007; - R and D tax credit of £0.6m received August 2007; and - Out licensing income of $1 million received in September 2007 * Cash at period end of £0.8 million (June 2006: £5.4 million) * Completion of one for thirty consolidation of the ordinary share capital * First time adoption of IFRS, including restatement of comparative periods Alan Goodman, Chairman of CeNeS, said: "CeNeS pipeline is focused and well balanced with clearly defined clinical and commercial targets. The Company is well placed to deliver important partnering deals from its lead programme M6G and I remain confident that M6G will become a successful product in the treatment of post-operative pain. CeNeS also has an active CNS 5161 Phase II programme and a promising early stage pipeline validated recently by a major CNS 7056 partnership with Ono in Japan. We look forward to the Company's future with confidence. Following the successful fundraising in August, CeNeS has a solid balance sheet, a strong Phase III lead programme backed up by good clinical data and an active earlier pipeline moving into Phase II and Phase I trials in the short term. The progress we have made to date and the exciting news flow ahead means that we are well placed to deliver significantly increased value to our shareholders." The full version of the report is available at www.cenes.com. ** For today only ** - Starting at 9.30am there will be a conference call and a presentation for analysts at the offices of Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London, WC2A 1PB. The conference call dial in details are as follows: UK and Europe: +44 (0)20 7806 1958 Access code 7949271 US participants: +1 718 354 1390 Access code 7949271 For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466 JMFinn Capital Markets Geoff Nash Tel: +44 (0)20 7600 1658 Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113 About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS website: www.cenes.com. The press release can be downloaded from the following link: --- End of Message --- CeNeS Pharmaceuticals Plc WKN: 913665; ISIN: GB0002070505; Listed: Freiverkehr in Börse Berlin, Freiverkehr in Frankfurter Wertpapierbörse;